AFT Pharmaceuticals (ASX:AFP, NZE:AFT) will start sales of its patented intravenous pain relief medicine, Maxigesic IV, in Canada this month through its Canadian unit, according to a Tuesday filing with the Australian and New Zealand bourses.
The company plans to launch additional over-the-counter products in fiscal 2026, the filing said.